Dr. Sumit Anil Shah, MD

Dr. Shah practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Shah's NPI, 1942529227, was assigned on May 25, 2010. Dr. Shah graduated from Stanford University School Of Medicine in 2010. Dr. Shah holds California license A120808.

Dr. Shah's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Shah's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Shah is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Shah to 1 more hospital, named with a free account. Dr. Shah's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shah practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shah's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Shah is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Shah's licenses on file in 2 states: California and Oregon.

Dmand AI lists bile duct problems, circulatory problems in extremities, gastrointestinal infection, high cholesterol, rash, tinnitus, tobacco use and underactive thyroid among the conditions Dr. Shah treats.

CMS data shows 1,852 Medicare services from Dr. Shah across 7 procedure codes in 2024, for 402 Medicare patients. Medicare paid $169,952 for them.

CMS counts 402 Medicare patients who saw Dr. Shah in 2024. The largest group is 75 to 84, with 181 patients. 75% of them have cancer, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shah's median patient age at 67, with 29% women.

In 2024, Dr. Shah wrote 442 Medicare Part D claims for 95 patients. 67% of them were for generic drugs. CMS names the drug for 359 of them, across 11 drugs with 11 or more claims each, at $1,248,700 in total drug cost. In 2023, CMS named 313 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Shah for performance year 2024, reported as part of a group. Dr. Shah accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shah as offering telehealth.

Dmand AI links 35 papers to Dr. Shah, published from 2011 to 2025. 2020 was the busiest year, with 6. The most frequent topics are COVID-19, SARS-CoV-2 and Urologic Neoplasms. Dr. Shah has published most often in JCO Oncol Pract. Dr. Shah's most frequent co-authors are Sumit Shah, MD, Mehmet Asim Bilen, MD and Alice Chen Fan, MD.

Dmand AI links Dr. Shah to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Renal Cell and Kidney Neoplasms.

CMS Open Payments shows 70 general payments to Dr. Shah from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Janssen Pharmaceuticals, Inc paid the most, $25,700.

Dr. Shah graduated from Stanford University School Of Medicine in 2010.

Dr. Shah is in network with 9 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.